2-(5-fluoro-2,3-dihydro-indol-1-yl)-ethylamine | 552866-94-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 2-(5-fluoro-2,3-dihydro-indol-1-yl)-ethylamine
• 英文别名: 1H-Indole-1-ethanamine, 5-fluoro-2,3-dihydro-；2-(5-fluoro-2,3-dihydroindol-1-yl)ethanamine
• CAS: 552866-94-1
• 化学式: C₁₀H₁₃FN₂
• 分子量: 180.225
• InChiKey: SFULMMUYADNYSA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  29.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(5-fluoro-2,3-dihydro-indol-1-yl)-ethylamine 、 (S)-3-cyclohexyl-2-hydroxypropanoic acid 在 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 二氯甲烷 为溶剂， 生成 3-cyclohexyl-N-[2-(5-fluoro-2,3-dihydro-indol-1-yl)-ethyl]-2-(S)-hydroxy-propionamide
  参考文献：
  名称：

  [EN] INHIBITORS OF CATHEPSIN S
  [FR] INHIBITEURS DE LA CATHEPSINE S

  摘要：

  公开号：

  WO2005034848A3
• 作为产物：
  描述：

  5-氟吲哚 在 sodium cyanoborohydride 作用下， 以 溶剂黄146 、 甲苯 为溶剂， 反应 36.0h， 生成 2-(5-fluoro-2,3-dihydro-indol-1-yl)-ethylamine
  参考文献：
  名称：

  Discovery of SB-705498: A potent, selective and orally bioavailable TRPV1 antagonist suitable for clinical development

  摘要：

  Small molecule antagonists of the vanilloid receptor TRPV1 (also known as VR1) are disclosed. Pyrrolidinyl ureas such as 8 and 15 (SB-705498) emerged as lead compounds following optimisation of the previously described urea SB-452533. Pharmacological studies using electrophysiological and FLIPR-Ca2+-based assays showed that compounds such as 8 and 15 were potent antagonists versus the multiple chemical and physical modes of TRPV1 activation (namely capsaicin, acid and noxious heat). Furthermore, 15 possessed suitable developability properties to enable progression of this compound into in vivo studies and subsequently clinical development. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.03.030

文献信息

• Arylaminoethyl carbamates as a novel series of potent and selective cathepsin S inhibitors
  作者：David C. Tully、Hong Liu、Arnab K. Chatterjee、Phil B. Alper、Jennifer A. Williams、Michael J. Roberts、Daniel Mutnick、David H. Woodmansee、Thomas Hollenbeck、Perry Gordon、Jonathan Chang、Tove Tuntland、Christine Tumanut、Jun Li、Jennifer L. Harris、Donald S. Karanewsky

  DOI：10.1016/j.bmcl.2006.07.032

  日期：2006.10

  We report a novel series of noncovalent inhibitors of cathepsin S. The synthesis of the peptidomimetic scaffold is described and structure-activity relationships of P3, P1, and P1' subunits are discussed. Lead optimization to a non-peptidic scaffold has resulted in a new class of potent, highly selective, and orally bioavailable cathepsin S inhibitors.

  我们报告了一系列新型的组织蛋白酶S非共价抑制剂。描述了拟肽支架的合成，并讨论了P3，P1和P1'亚基的构效关系。对非肽支架的前导优化导致了一类新的有效，高选择性和口服生物利用的组织蛋白酶S抑制剂。
• BIARYL-SUBSTITUTED TETRAHYDRO-PYRAZOLO-PYRIDINE MODULATORS OF CATHEPSIN S
  申请人：Allen Darin

  公开号：US20080207683A1

  公开（公告）日：2008-08-28

  Biaryl-substituted tetrahydro-pyrazolo-pyridine compounds are described, which are useful as cathepsin S modulators. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by cathepsin S activity, such as psoriasis, pain, multiple sclerosis, atherosclerosis, and rheumatoid arthritis.

  所述的双芳基取代的四氢吡唑吡啶化合物被描述为对半胱氨酸蛋白酶S的调节剂。这些化合物可用于制备药物组合物和治疗由半胱氨酸蛋白酶S活性介导的疾病状态、疾病和病况的方法，如银屑病、疼痛、多发性硬化、动脉粥样硬化和类风湿性关节炎。
• Novel compounds
  申请人：Rami Kantilal Harshad

  公开号：US20060100202A1

  公开（公告）日：2006-05-11

  Compounds of formula (I) or a pharmaceutically acceptable salt or solvate thereof: wherein, R 1 , R 2 , P, p and n are as defined in the specification, a process for preparing such compounds, a pharmaceutical composition containing such compounds and the use of such compounds in medicine.

  式(I)的化合物或其药学上可接受的盐或溶剂，其中，R1，R2，P，p和n如规范中所定义，制备这种化合物的过程，包含这种化合物的药物组成物，以及这种化合物在医学上的用途。
• Inhibitors of cathepsin S
  申请人：Liu Hong

  公开号：US20050113356A1

  公开（公告）日：2005-05-26

  The present invention provides compounds, compositions and methods for the selective inhibition of cathepsin S. In a preferred aspect, cathepsin S is selectively inhibited in the presence of at least one other cathepsin isozyme. The present invention also provides methods for treating a disease state in a subject by selectively inhibiting cathepsin S.

  本发明提供了一种选择性抑制蛋白酶S的化合物、组合物和方法。在一个优选方面，当至少存在另一种蛋白酶同工酶时，选择性抑制蛋白酶S。本发明还提供了通过选择性抑制蛋白酶S治疗主体疾病状态的方法。
• INHIBITORS OF CATHEPSIN S
  申请人：Liu Hong

  公开号：US20070123523A1

  公开（公告）日：2007-05-31

  The present invention provides compounds, compositions and methods for the selective inhibition of cathepsin S. In a preferred aspect, cathepsin S is selectively inhibited in the presence of at least one other cathepsin isozyme. The present invention also provides methods for treating a disease state in a subject by selectively inhibiting cathepsin S.

  本发明提供了一种选择性抑制蛋白酶S的化合物、组合物和方法。在一种优选方面，当存在至少一种其他蛋白酶同工酶时，选择性地抑制蛋白酶S。本发明还提供了通过选择性抑制蛋白酶S治疗主体的疾病状态的方法。